Business
Exercise of Options and Total Voting Rights
Exercise of Options and Total Voting Rights.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2114I\n Fusion Antibodies PLC\n 10 August 2021\n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n \n \n Exercise of Options and Total Voting Rights\n \n \n \n \n Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM (\"Admission\") of 23,334 new ordinary shares of 4p each in the Company (\"New Ordinary Shares\"). The New Ordinary Shares are being issued pursuant to the exercise of options by an employee of the Company. The options were issued pursuant to the Company's EMI Employee Share Option Scheme with an exercise price of 54.5p. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares and Admission is expected to become effective on 17 August 2021. \n \n \n Total Voting Rights\n \n \n \n On Admission, the issued share capital of the Company will comprise 25,894,946 ordinary shares of 4 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission, the total number of Ordinary Shares and voting rights in the Company will be 25,894,946. From Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n Enquiries: \n \n \n \n \n \n Fusion Antibodies plc\n \n \n www.fusionantibodies.com\n \n \n \n \n Richard Jones, Chief Executive Officer\n James Fair, Chief Financial Officer\n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n James Reeve (Corporate Finance)\n Tony Quirke (Sales and Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n Tel: +44 (0)20 7933 8780 or [email protected]\n \n \n \n \n An...